a phase 1 study of nivolumab bms

results for this questionFeedbackA Phase 1 Study of Nivolumab (BMS-936558) in Subjects

Aug 08,2008·A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies (MDX1106-03) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.Listing a study does not mean it has been evaluated by the U.S.Federal Government.Read our disclaimer for details. results for this questionHow much Nivo is in bms-986178 monotherapy?How much Nivo is in bms-986178 monotherapy?During escalation,patients received BMS-986178 monotherapy 20-320 mg IV Q2W,BMS-986178 20-320 mg + NIVO 240 mg IV Q2W,or BMS-986178 20-320 mg + IPI 1 mg/kg IV Q3W.Abstract LB-127 From bench to bedside Exploring OX40 receptor mod

results for this questionWhen to discontinue nivolumab prior to radiotherapy?When to discontinue nivolumab prior to radiotherapy?Prior focal radiotherapy completed at least 2 weeks prior to study drug administration Immunosuppressive doses of systemic medications,such as steroids or absorbed topical steroids must be discontinued at least 2 weeks before study drug administrationA Phase 1 Study of Nivolumab (BMS-936558) in Subjects With results for this questionWhen to take nivolumab 240 mg for PTS?When to take nivolumab 240 mg for PTS?Pts were PD-L1unselected with newly diagnosed,previously untreated,resectable,HPV+ or HPV SCCHN of the oral cavity,pharynx,or larynx with T1 or greater primary lesions and N1 or greater nodal disease.Pts were to receive nivolumab 240mg on days 1 and 15 and surgery on day 29 ± 7.An Open-label,Multicohort,Phase 1/2 Study in Patients A Phase 1 2a Study of BMS 986178 Administered Alone and

A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab and/or Ipilimumab in Advanced Solid Tumors (OPEN for TNBC Part 9 only) Description The purpose of the study is to test the safety of an investigational drug called BMS-986178 (also known as anti OX-40 antibody) administered alone and in combination with

A Phase 1/2a Study of BMS-986179 Administered Alone and

A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors Status Active,no longer recruiting.Phase of Trial Phase I/II Latest Information Update 17 Feb 2021.PriceA Phase 1/2a Study of BMS-986205 Administered in A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558,anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors.Cancer Answer Line 866.223.8100; Details.IRB Study Number 17-240 Status Active,not recruiting A Phase I Study of Immunotherapy with BMS-986016 AloneA Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety,Tolerability,and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab,BMS-936558) in Advanced Solid Tumors Purpose.Nivolumab is a form of immunotherapy.

Actual Enrollment 395 participantsIntervention Model Single Group AssignmentAllocation Non-RandomizedStudy Type Interventional (Clinical Trial)Preliminary Results of a Phase I Study of Nivolumab (BMS

Dec 06,2014·Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies Alexander M.Lesokhin,MD,Alexander M.Lesokhin,MD 1 Memorial Sloan Kettering Cancer Center,New York,NY .Breathing Labs Cancers Free Full-Text Irreversible Aug 04,2021·Author Response.docx.Reviewer 2 Report.Geboers and al.present an original Phase I trial,randomized and controlled devoted to pancreatic cancer patients with a stage IV tumor and at least as a second phase treatment.3 arms have been designed A nivolumab as control; B nivolumab + tumor electroporation; C nivolumab + tumor electroporation after IV injection of TLR ligandBristol Myers Squibb - One- Two-Year Survival Rates of Jun.2,2014- Bristol-Myers Squibb Company (NYSE BMY) today announced follow up results from Study -004,a multi-arm Phase 1b dose-ranging trial evaluating the safety and activity of the combination regimen of nivolumab,an investigational PD-1 immune checkpoint inhibitor,and Yervoy &(ipilimumab) given either concurrently or sequentially in patients with advanced melanoma (n=127).

Bristol-Myers Squibb and Five Prime Present Phase 1a/1b

·From bench to bedside Exploring OX40 receptor modulation in a phase 1/2a study of the OX40 costimulatory agonist BMS-986178 ± nivolumab (NIVO) or ipilimumab (IPI) in patients with advanced solid tumors [abstract].In Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago,IL.Cited by 10785Publish Year 2012Author Suzanne L.Topalian,F.Stephen Hodi,Julie R.Brahmer,Scott N.Gettinger,David C.Smith,David F.An Open-label,Multicohort,Phase 1/2 Study in Patients Nivolumab was well tolerated,with no surgery delay due to TRAEs.Nivolumab led to tumor reductions within 1 month in nearly half of evaluable pts.Clinical trial identification.NCT02488759.Legal entity responsible for the study.Bristol-Myers Squibb.Funding.Bristol-Myers Squibb.DisclosureCited by 10Publish Year 2020Author Zev A.Wainberg,Howard S.Hochster,Edward J.Kim,Ben George,Aparna Kaylan,E.Gabriela Chiorean,Phase I study of Nivolumab,an anti-PD-1 antibody,in phase I single-dose study in which the mean t 1/2 was 17 to 24.8 days for nivolumab at doses of 0.3 to 10 mg/kg (unpub-lished data ClinicalTrials.gov [NCT00441337]).Dose-limiting toxicity (DLT) was defined as any adverse event (AE) occurring up to 7 weeks after the first nivolumab treatmentthatfulfilledanyofthefollowingcriteriaandforwhich

Cited by 10Publish Year 2020Author Zev A.Wainberg,Howard S.Hochster,Edward J.Kim,Ben George,Aparna Kaylan,E.Gabriela Chiorean,Safety,Tolerability,and Potential Clinical Activity of a

Design,setting,and participants This global,open-label,phase 1/2a study of BMS-986156 with or without nivolumab enrolled 292 patients 18 years or older with advanced solid tumors and an Eastern Cooperative Oncology Group performance status of 1 or less.Cited by 117Publish Year 2016Author Stephen Ansell,Martin E Gutierrez,Margaret A.Shipp,Douglas Gladstone,Alison Moskowitz,Ivan BorPhase 1b/2 study of nivolumab in combination with an anti Here we describe a phase 1b/2 study of the combination of BMS-986253 plus nivolumab in a biomarker-enriched population of pts with advanced cancers (NCT03400332).Methods This is a 2-part study with an enrollment of 260 target selected pts,aged 18 y with advanced solid tumors.Pts must have 1 measurable lesion at baseline per Cited by 186Publish Year 2014Author Alexander M.Lesokhin,Stephen M.Ansell,Philippe Armand,Emma C.Scott,Ahmad Halwani,Martin GutiA Phase 1 Study of Nivolumab in Combination with Dec 02,2016·Introduction Nivolumab (nivo) is a fully human IgG4 monoclonal antibody (mAb) targeting programmed death receptor-1 (PD-1).Nivo has demonstrated clinical activity and an acceptable safety profile in a phase 1b study (NCT01592370; CheckMate 039) in patients (pts) with relapsed/refractory hematologic malignancies.

Cited by 22Publish Year 2020Author Kimberley M.Heinhuis,Matteo Carlino,Markus Joerger,Massimo Di Nicola,Tarek Meniawy,Sylvie RottEstimated Reading Time 6 minsA Phase 1 Study of Nivolumab (BMS-936558) in Subjects

The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer.Another purpose is to determine how MDX-1106 is absorbed and distributed within the body,and how it's eventually eliminated. A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Cited by 3Publish Year 2018Author Ignacio Melero Bermejo,Elizabeth M.Jaffee,Diwakar Davar,Josephine Cardarelli,Daphne Williams,POpen-label,Phase I Study of Nivolumab Combined with nab Open-label,Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer The safety profile of nivolumab plus <i>nab</i>-paclitaxel and gemcitabine at standard doses in advanced pancreatic cancer was manageable,with no unexpected safety signals.Cited by 49Publish Year 2017Author Noboru Yamamoto,Hiroshi Nokihara,Yasuhide Yamada,Takashi Shibata,Yosuke Tamura,Yoshitaka Seki,Estimated Reading Time 10 minsOpen-Label,Phase 1 Study of Nivolumab CombinedJun 18,2020·1 1 Open-Label,Phase 1 Study of Nivolumab Combined With nab-Paclitaxel Plus 2 Gemcitabine in Advanced Pancreatic Cancer 3 4 Zev A.Wainberg,1 Howard S.Hochster,2 Edward J.Kim,3 Ben George,4 Aparna Kaylan,5 E.5 Gabriela Chiorean,6 David M.Waterhouse,7 Martin Guiterrez,8 Aparna Parikh,9 Rishi Jain,10 6 Daniel Ricardo Carrizosa,11 Hatem H.Soliman,12

Cited by 49Publish Year 2017Author Noboru Yamamoto,Hiroshi Nokihara,Yasuhide Yamada,Takashi Shibata,Yosuke Tamura,Yoshitaka Seki,Phase I study of Nivolumab,an anti-PD-1 antibody,in

Dec 08,2016·Nivolumab was well tolerated when administered in a single dose at up to 10 mg/kg,with a mean half-life (t 1/2) of 17 to 24.8 days in an early Phase I study (unpublished data ClinicalTrials.gov [NCT00441337]).Cited by 5Publish Year 2018Author Rui Wang,Yan Feng,Ed Hilt,Xiling Yuan,Chan Gao,Xiao Shao,Yongliang Sun,Michael D'silva,KatheEstimated Reading Time 4 minsBristol Myers Squibb - Promising Response Rates with Jun 05,2016·PRINCETON,N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) announced today the first presentation of results for Opdivo in the cohort of patients with metastatic urothelial cancer (n=78),the most common type of bladder cancer,after platinum-based therapy from CheckMate -032,a Phase 1/2 open-label trial.Clinical Trials The Johns Hopkins Melanoma ProgramJ1814 - J1814 - A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027-002).This study tests nivolumab plus anti-interleukin-8 in patients with unresectable or metastatic cancers,including melanoma.

Images of A Phase 1 study of Nivolumab Bms

imagesSome results are removed in response to a notice of local law requirement.For more information,please see here.12345NextLayout table for study informationPhase 1/2a First-In-Human Study of BMS-986207Jun 17,2021·Phase The purpose of the study is to test the safety of an investigational/study drug called BMS-986207 (also known as Anti TIGIT monoclonal antibody) administered alone,in combination with nivolumab,and in combination with nivolumab and ipilimumab.This study will investigate how research subjects/participants with advanced solid tumors tolerate these drugs and identify the highest dose or most suitable dose,of BMS-986207 alone,in combination with nivolumab,

Phase 1Start date January 2009Sponsor Bristol-Myers SquibbStatus Active not recruitingBristol Myers Squibb - Five-Year Survival Observed With

Apr 03,2017·Estimated five-year overall survival rate in previously treated advanced NSCLC patients who received Opdivo was 16%; survival was observed across PD-L1 expression levels and tumor histologies Data represent the longest survival follow-up with an anti-PD-1 therapy in advanced NSCLC Bristol-Myers Squibb Company (NYSE:BMY) today announced the first report of five-year overall survival (OS) data from the Phase 1 dose-ranging studyPositive Phase 3 Data for Opdivo (nivolumab) in - BMSSep 29,2014·PRINCETON,N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) today announced positive results from CheckMate -037,a Phase 3 randomized,controlled open-label study of Opdivo (nivolumab),an investigational PD-1 immune checkpoint inhibitor,versus investigators choice chemotherapy (ICC) in patients with advanced melanoma who Safety,Activity,and Immune Correlates of AntiPD-1 This phase 1 study assessed the safety,antitumor activity,and pharmacokinetics of BMS-936558,a fully human IgG4-blocking monoclonal antibody directed against PD-1,in patients with selected

Safety,Tolerability,and Potential Clinical Activity of a

Jan 01,2020·In the present study,results are reported from a phase 1/2a dose-escalation and dose-expansion study investigating the safety,tolerability,pharmacokinetics,pharmacodynamics,and preliminary clinical activity profiles of BMS-986156 as monotherapy treatment and in combination with nivolumab in patients with advanced solid tumors (NCT02598960).30Study Explores Anti-PVRIG Therapy Plus Nivolumab and Anti Jul 28,2021·The first patient with an advanced solid tumor has been dosed with the first-in-class anti-PVRIG antibody,COM701,in combination with nivolumab (Opdivo) and the anti-TIGIT antibody,BMS-986207,in a phase 1/2 clinical trial (NCT04570839),according to a press release from Compugen Ltd.Study Type :Interventional (Clinical Trial) Official Title:A Phase 1,Open-Label,Multicenter,Mult Actual Study Start Date :January 22,2009 Actual Primary Completion Date :February 4,2013 Estimated Study Completion Date :September 14,2020 5 more rows Jul 1 2021Actual Enrollment :395 participantsAllocation:Non-RandomizedIntervention Model:Single Group AssignmentStudy Type :Interventional (Clinical Trial)A Phase 1 Study of Nivolumab (BMS-936558) in Subjects WWas this helpful?People also askWhat was the abstract for the nivolumab Phase 1 study?What was the abstract for the nivolumab Phase 1 study?From bench to bedside Exploring OX40 receptor modulation in a phase 1/2a study of the OX40 costimulatory agonist BMS-986178 ± nivolumab (NIVO) or ipilimumab (IPI) in patients with advanced solid tumors [abstract].In Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago,IL.Abstract LB-127 From bench to bedside Exploring OX40 receptor mod

Related Post

Leave a message